Furthermore, a faster and more severe evolution/progression of the disease is observed in pediatric NAFLD patients compared to adults [11,48,49] and we hypothesize that the elevated levels of TGF-β could be a marker of this condition in pediatric population, although we failed to formally demonstrate that levels of this biomarker directly reads progression of hepatis steatosis. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatotic liver disease.